• Investing Daily
  • Premium Services
    • Income Millionaire
    • Options for Income
    • Personal Finance
    • Profit Catalyst Alert
    • Radical Wealth Alliance
    • Real World Investing
    • Systematic Wealth
    • The Complete Investor
    • Utility Forecaster
    • Velocity Trader
    • Wealth Society
  • Investing Topics
    • Stock Market Investing
    • Resources
    • Options Strategy Lessons
    • Dividend Investing
    • Stocks to Watch
    • Forecasts
  • Analysts
    • Jim Pearce
    • Jim Fink
    • Robert Rapier
    • Stephen Leeb
    • Scott Chan
    • John Persinos
  • Help Center
  • Log In
  • Help Center
  • Log In

Investing Daily logo

  • Premium Services
    • Income Millionaire
    • Options for Income
    • Personal Finance
    • Profit Catalyst Alert
    • Radical Wealth Alliance
    • Real World Investing
    • Systematic Wealth
    • The Complete Investor
    • Utility Forecaster
    • Velocity Trader
    • Wealth Society
  • Investing Topics
    • Stock Market Investing
    • Resources
    • Options Strategy Lessons
    • Dividend Investing
    • Stocks to Watch
    • Forecasts
  • Analysts
    • Jim Pearce
    • Jim Fink
    • Robert Rapier
    • Stephen Leeb
    • Scott Chan
    • John Persinos
Forecasts

Our AT&T Stock Prediction In 2019 (Buy or Sell?)

As AT&T grapples with the multi-media revolution, can this legacy telecom light a fire under its lagging stock price? Read More

Our AT&T Stock Prediction In 2019 (Buy or Sell?)

Q&A: Tariffs, Interest Rates, Black Swans…and More

Our Visa Stock Prediction In 2019 (Buy or Sell?)

Our NetApp Stock Prediction in 2019 (Buy or Sell?)

  • Our Exxon Mobil Stock Prediction in 2019 (Buy or Sell?)

    Our Exxon Mobil Stock Prediction in 2019 (Buy or Sell?)

    Exxon Mobil stock is highly leveraged to the price of oil. So, if oil prices recover in 2019, XOM's share price should should spike higher. Read More

  • Options Trading: “Rho” Explained (Simple Guide)

    Options Trading: “Rho” Explained (Simple Guide)

    Rho is a gauge that helps you evaluate options contracts and their exposure to the risk of interest rate fluctuations. Here's how it works. Read More

  • Beta: A Proven Tool to Estimate Risk

    Beta: A Proven Tool to Estimate Risk

    We frequently advise investors to know their risk tolerance. Here's a time-tested measure for understanding the potential volatility in your portfolio. Read More

  • Our Bravatek Solutions Stock Prediction in 2019 (Buy or Sell?)

    Our Bravatek Solutions Stock Prediction in 2019 (Buy or Sell?)

    The rising incidence of hacking dominates the front pages. We examine cybersecurity firm Bravatek to see if it's a growth play or just another risky fad stock. Read More

  • Our Nike Prediction in 2019 (Buy or Sell?)

    Our Nike Prediction in 2019 (Buy or Sell?)

    Nike is one of the most recognizable brands in the world. The company has faced some stiff competition lately. Will it remain Number One? Read More

  • Our Accenture Stock Prediction in 2019 (Buy or Sell?)

    Our Accenture Stock Prediction in 2019 (Buy or Sell?)

    This global colossus dominates the thriving management consulting industry. But as the pace of change accelerates, can the company stay on top? Read More

  • Top 3 Best Cyclical Stocks to Own (2019 Review)

    Top 3 Best Cyclical Stocks to Own (2019 Review)

    There's a trio of economic trends that will drive the market higher this year. Shareholders of these three companies stand to benefit the most. Read More

  • Our Therapix Biosciences Stock Prediction in 2019 (Buy or Sell?)

    Our Therapix Biosciences Stock Prediction in 2019 (Buy or Sell?)

    An examination of Therapix Biosciences, its rivals, and a prediction for this micro-cap biotech stock in 2019. Will Therapix prove a winner or loser in the race to develop cannabis-based drugs? Read More

  • Our Supreme Cannabis Stock Prediction in 2019 (Buy or Sell?)

    Our Supreme Cannabis Stock Prediction in 2019 (Buy or Sell?)

    An examination of Supreme Cannabis stock, its rivals, whether it's overpriced or underpriced, and a prediction for the stock in 2019. Read More

  • Will Amazon Take Over the Federal Government?

    Will Amazon Take Over the Federal Government?

    Amazon's new headquarters near Washington DC could elevate Jeff Bezos’ legacy to something far greater than being remembered as the guy that wrecked retail. Read More

  • Our Cara Therapeutics Stock Prediction in 2019 (Buy or Sell?)

    Our Cara Therapeutics Stock Prediction in 2019 (Buy or Sell?)

    Our review of clinical-stage medical cannabis companies continues, with a fledgling biotech that's generating especially keen interest on Wall Street. Is Cara a future bonanza... or short-term fad? Read More

  • Our Corbus Pharmaceuticals Stock Prediction in 2019 (Buy or Sell?)

    Our Corbus Pharmaceuticals Stock Prediction in 2019 (Buy or Sell?)

    We examine a clinical-stage biotech making medicines from cannabis. Is the stock a hot prospect or is all the hype just a smokescreen for a fundamentally weak investment? Read More

  • Our Intec Pharma Stock Prediction in 2019 (Buy or Sell?)

    Our Intec Pharma Stock Prediction in 2019 (Buy or Sell?)

    We spotlight Intec Pharma, its rivals, and whether the stock is overpriced or underpriced. Is this Israel-based biotech on the verge of launching blockbuster new drugs? Read More

  • The Life-Changing Magic of Tidying Up Your Portfolio

    The Life-Changing Magic of Tidying Up Your Portfolio

    Marie Kondo's famous book on cleaning out your closet contains some helpful hints that are easily applied to your portfolio. Use this mid-winter bounce to clean out your stocks. Read More

  • Our Insys Therapeutics Stock Prediction in 2019 (Buy or Sell?)

    Our Insys Therapeutics Stock Prediction in 2019 (Buy or Sell?)

    An examination of this popular biotech stock, its rivals, whether it's overpriced or underpriced, and a prediction for its prospects in 2019. Read More

  • Our Zynerba Pharmaceuticals Stock Prediction in 2019 (Buy or Sell?)

    Our Zynerba Pharmaceuticals Stock Prediction in 2019 (Buy or Sell?)

    Zynerba Pharmaceuticals is a fledgling, small-cap maker of cannabis-based drugs. The stock has attracted considerable media interest, but is it too risky? We sift through the hype to examine the fundamentals. Read More

Market Overview

Analysts

Jim Pearce

Jim Pearce

Bio | Archive

Publications: Personal Finance, Systematic Wealth, Income Millionaire, Radical Wealth Alliance

Jim Fink

Jim Fink

Bio | Archive

Publications: Options for Income, Velocity Trader, Personal Finance, Radical Wealth Alliance

Robert Rapier

Robert Rapier

Bio | Archive

Publications: Utility Forecaster, Personal Finance, Radical Wealth Alliance

Stephen Leeb

Stephen Leeb

Bio | Archive

Publications: The Complete Investor, Real World Investing, Radical Wealth Alliance

Scott Chan

Scott Chan

Bio | Archive

Publications: Real World Investing, The Complete Investor, Radical Wealth Alliance

John Persinos

John Persinos

Bio | Archive

Publications: Personal Finance, Utility Forecaster, Radical Wealth Alliance and Mind Over Markets

Free E-letters

Congratulations!

You've successfully been signed up for our free e-Letter(s)!

We offer a variety of FREE analysis delivered weekly to your inbox. Select the E-letters you wish to receive and enter your email below.

Please Select At Least One

Please Enter A Valid Email Address

Sign Up for these FREE E-Letters Sign Up for Free
  • Home
  • Events
  • Terms and Conditions
  • Media Inquiries
  • White List
  • Privacy Policy
  • About Us
  • Contact Us
Investing Daily is not a registered investment adviser or broker/dealer. All information provided on the Investing Daily network of websites is provided as-is and does not represent personalized investment advice. These sites do not constitute a representation by the publisher or a solicitation for the purchase or sale of securities. All opinions provided are based on sources believed to be reliable and are written in good faith, but no warranty or representation, expressed or implied, is made as to their accuracy. There are risks associated with any investment and we strongly encourage readers to supplement the information in these articles, special reports, and newsletters with independent research and other professional advice before investing in any security.
Copyright © 2019 Investing Daily, a division of Capitol Information Group, Inc. All rights reserved.